DOP2021000197A - Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea - Google Patents
Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutáneaInfo
- Publication number
- DOP2021000197A DOP2021000197A DO2021000197A DO2021000197A DOP2021000197A DO P2021000197 A DOP2021000197 A DO P2021000197A DO 2021000197 A DO2021000197 A DO 2021000197A DO 2021000197 A DO2021000197 A DO 2021000197A DO P2021000197 A DOP2021000197 A DO P2021000197A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pharmaceutical composition
- human
- variant
- drug
- present
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 title 1
- 238000010254 subcutaneous injection Methods 0.000 title 1
- 239000007929 subcutaneous injection Substances 0.000 title 1
- 101100178973 Homo sapiens SPAM1 gene Proteins 0.000 abstract 4
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende (a) un fármaco y (b) una variante de PH20 humana. La variante de PH20 humana incluida en la composición farmacéutica de acuerdo con la presente invención, incluye sustituciones de residuos de aminoácidos en una o más regiones seleccionadas de una región de hélice alfa 8 (S347 a C381) y una región enlazadora (A333 a R346) entre hélice alfa 7 y hélice alfa 8 en PH20 humana de tipo natural, que tiene la secuencia de aminoácidos de la SEQ ID NO: 1, donde los residuos de aminoácidos ubicados en el extremo N-terminal o en el C-terminal son escindidos selectivamente. Asimismo, la composición farmacéutica de acuerdo con la presente invención podría incluir además un aditivo farmacéuticamente aceptable, específicamente un estabilizador. La composición farmacéutica de acuerdo con la presente invención puede maximizar el efecto terapéutico de un fármaco usado en combinación con la misma, debido al efecto de las variantes de PH20 humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190033880 | 2019-03-25 | ||
PCT/KR2020/003975 WO2020197230A1 (ko) | 2019-03-25 | 2020-03-24 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2021000197A true DOP2021000197A (es) | 2021-11-15 |
Family
ID=72611090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2021000197A DOP2021000197A (es) | 2019-03-25 | 2021-09-22 | Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea |
Country Status (23)
Country | Link |
---|---|
US (2) | US20210363270A1 (es) |
EP (1) | EP3785701A4 (es) |
JP (3) | JP7295150B2 (es) |
KR (3) | KR102650991B1 (es) |
CN (3) | CN116870164B (es) |
AU (2) | AU2020248612B9 (es) |
BR (1) | BR112021019076A2 (es) |
CA (1) | CA3131052A1 (es) |
CL (1) | CL2021002464A1 (es) |
CO (1) | CO2021012380A2 (es) |
CR (1) | CR20210489A (es) |
DO (1) | DOP2021000197A (es) |
EA (1) | EA202192588A1 (es) |
EC (1) | ECSP21070640A (es) |
IL (1) | IL286539A (es) |
JO (1) | JOP20210262A1 (es) |
MX (1) | MX2021011278A (es) |
NI (1) | NI202100085A (es) |
PE (1) | PE20220283A1 (es) |
SA (1) | SA521430398B1 (es) |
SG (1) | SG11202110512WA (es) |
WO (1) | WO2020197230A1 (es) |
ZA (2) | ZA202108027B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3130347T (lt) | 2011-12-30 | 2019-10-25 | Halozyme Inc | Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
MA52570A (fr) | 2018-05-10 | 2021-03-17 | Regeneron Pharma | Formulations contenant des protéines de fusion du récepteur vegf à haute concentration |
CN111971387A (zh) * | 2018-07-25 | 2020-11-20 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US20230250408A1 (en) * | 2020-01-23 | 2023-08-10 | Alteogen Inc. | Novel hyaluronidase variants with improved stability and pharmaceutical composition comprising the same |
MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
CA3201348A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Antibody compositions and methods of use thereof |
MX2024001631A (es) | 2021-08-02 | 2024-04-19 | argenx BV | Formas de dosificación unitaria subcutánea. |
KR20240055077A (ko) | 2021-09-14 | 2024-04-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 히알루로니데이스를 이용한 농축된 항체 제형의 촉진된 전달 |
AU2022376750A1 (en) * | 2021-10-29 | 2024-05-16 | Alteogen Inc. | Pharmaceutical composition comprising human hyaluronidase ph20 and drug |
WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
WO2023169986A1 (en) * | 2022-03-07 | 2023-09-14 | Mabxience Research, S.L. | Stable formulations for antibodies |
WO2023204554A1 (ko) * | 2022-04-20 | 2023-10-26 | 주식회사 알토스바이오로직스 | 오크렐리주맙을 포함하는 약학적 조성물과 그의 용도 |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
CA3240340A1 (en) * | 2022-06-22 | 2023-12-28 | Soon Jae Park | N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof |
WO2024005502A1 (ko) * | 2022-06-29 | 2024-01-04 | 주식회사 오디스젠 | 중성 ph에서 활성을 나타내는 히알루로니다제 hyal1 변이체 |
KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
WO2024117476A1 (ko) * | 2022-11-28 | 2024-06-06 | 주식회사 대웅제약 | 생체이용률이 개선된 니클로사마이드 함유 조성물 |
KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ542873A (en) * | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
CN101384621A (zh) * | 2005-11-10 | 2009-03-11 | 受体生物公司 | 产生受体和配体同种型的方法 |
TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
EP2285402A2 (en) * | 2008-04-14 | 2011-02-23 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
EP3037529B1 (en) * | 2008-12-09 | 2019-03-27 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
LT3130347T (lt) | 2011-12-30 | 2019-10-25 | Halozyme Inc | Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas |
TW201534726A (zh) * | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
US20170218382A1 (en) * | 2014-07-31 | 2017-08-03 | National University Corporation Kobe University | Secretion Signal Peptide, And Protein Secretory Production And Cell Surface Display Using Said Secretion Signal Peptide |
PT3186281T (pt) | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
TW201825121A (zh) * | 2016-11-30 | 2018-07-16 | 美國紀念斯隆-凱特琳癌症中心 | 抑制劑—功能化超微小奈米粒子及其方法 |
KR20230144110A (ko) * | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN111971387A (zh) * | 2018-07-25 | 2020-11-20 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
-
2020
- 2020-03-24 CN CN202310416462.0A patent/CN116870164B/zh active Active
- 2020-03-24 US US17/052,952 patent/US20210363270A1/en active Pending
- 2020-03-24 CA CA3131052A patent/CA3131052A1/en active Pending
- 2020-03-24 WO PCT/KR2020/003975 patent/WO2020197230A1/ko active Application Filing
- 2020-03-24 KR KR1020207030248A patent/KR102650991B1/ko active IP Right Grant
- 2020-03-24 CR CR20210489A patent/CR20210489A/es unknown
- 2020-03-24 JP JP2020569741A patent/JP7295150B2/ja active Active
- 2020-03-24 CN CN202080003052.8A patent/CN112203642A/zh active Pending
- 2020-03-24 AU AU2020248612A patent/AU2020248612B9/en active Active
- 2020-03-24 CN CN202310758097.1A patent/CN117100867A/zh active Pending
- 2020-03-24 BR BR112021019076A patent/BR112021019076A2/pt unknown
- 2020-03-24 MX MX2021011278A patent/MX2021011278A/es unknown
- 2020-03-24 SG SG11202110512WA patent/SG11202110512WA/en unknown
- 2020-03-24 JO JOP/2021/0262A patent/JOP20210262A1/ar unknown
- 2020-03-24 PE PE2021001563A patent/PE20220283A1/es unknown
- 2020-03-24 KR KR1020237007559A patent/KR20230037691A/ko active Search and Examination
- 2020-03-24 KR KR1020227016935A patent/KR102507853B1/ko active IP Right Grant
- 2020-03-24 EA EA202192588A patent/EA202192588A1/ru unknown
- 2020-03-24 EP EP20776465.5A patent/EP3785701A4/en active Pending
-
2021
- 2021-09-19 IL IL286539A patent/IL286539A/en unknown
- 2021-09-22 CL CL2021002464A patent/CL2021002464A1/es unknown
- 2021-09-22 NI NI202100085A patent/NI202100085A/es unknown
- 2021-09-22 DO DO2021000197A patent/DOP2021000197A/es unknown
- 2021-09-22 EC ECSENADI202170640A patent/ECSP21070640A/es unknown
- 2021-09-22 CO CONC2021/0012380A patent/CO2021012380A2/es unknown
- 2021-09-24 SA SA521430398A patent/SA521430398B1/ar unknown
- 2021-10-20 ZA ZA2021/08027A patent/ZA202108027B/en unknown
-
2022
- 2022-04-18 JP JP2022068166A patent/JP7166478B2/ja active Active
- 2022-05-13 US US17/744,575 patent/US20220289864A1/en active Pending
- 2022-08-22 ZA ZA2022/09369A patent/ZA202209369B/en unknown
-
2023
- 2023-02-24 JP JP2023026863A patent/JP2023078146A/ja active Pending
-
2024
- 2024-02-23 AU AU2024201238A patent/AU2024201238A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2021000197A (es) | Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea | |
AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
MX2020009824A (es) | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. | |
CO6190536A2 (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores | |
DE60031792D1 (de) | Schimärische amyloid-beta peptide | |
PE20191203A1 (es) | Variantes de alfa-glucosidasa acida y usos de las mismas | |
AR093626A1 (es) | Proteinas de fusion de enzima lisosomal y usos de las mismas | |
AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
PE20120792A1 (es) | Variantes de peptidos natriureticos de tipo c | |
PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
DK1877435T3 (da) | Glucagon-lignende peptid 2 (GLP-2)-analoger | |
AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
MX2022008060A (es) | Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. | |
PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
PE20090932A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 | |
AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
PE20201254A1 (es) | Analogos de compstatina y sus usos medicos | |
AR096927A1 (es) | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 | |
PE20220500A1 (es) | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 | |
PE20210185A1 (es) | Apirasas solubilizadas, metodos y usos | |
AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
AR061825A1 (es) | Analogos del peptido intestinal vasoactivo (vip) | |
BR0318594A (pt) | proteìna recombinante que possui um efeito anticancerìgeno, seu gene de codificação e usos desta |